相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia
Llucia Alberti-Servera et al.
BLOOD (2021)
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial
Franco Locatelli et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Achieving clinical success with BET inhibitors as anti-cancer agents
Tatiana Shorstova et al.
BRITISH JOURNAL OF CANCER (2021)
Targeting chemokines for acute lymphoblastic leukemia therapy
Zixi Hong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia
Monia Lunghi et al.
LEUKEMIA & LYMPHOMA (2021)
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Guillaume Richard-Carpentier et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
Yishai Ofran et al.
LEUKEMIA (2020)
Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
Jing Pan et al.
BLOOD (2020)
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia
C. Quintarelli et al.
LEUKEMIA (2020)
Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia
Nicola Goekbuget et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia A Randomized Clinical Trial
Shuhong Shen et al.
JAMA ONCOLOGY (2020)
High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia
Stephan Mueller et al.
FRONTIERS IN IMMUNOLOGY (2020)
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Sumit Gupta et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.
Mingzhi Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy
Prashant Ramesh Tembhare et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts
Florian Perner et al.
BLOOD (2020)
Rheumatoid arthritis and sickle cell disease: A potential association
Suely Roizenblatt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
Elias Jabbour et al.
Lancet Haematology (2020)
Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
Kimberly P. Dunsmore et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Robin Foa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival
Agne Taraseviciute et al.
BLOOD (2020)
Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231
David T. Teachey et al.
BLOOD (2020)
Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)
Franco Locatelli et al.
BLOOD (2020)
Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial
Abhishek Maiti et al.
BLOOD (2020)
Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Jeffrey E. Rubnitz et al.
BLOOD (2020)
A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study
Erica Brivio et al.
BLOOD (2020)
Tandem CD19/CD22 Dual Targets CART Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study
Wei Cui et al.
BLOOD (2020)
Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement
Valentina Nardi et al.
BLOOD ADVANCES (2020)
Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia
Diego Sanchez-Martinez et al.
BLOOD (2019)
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
CANCER (2019)
Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia
Ernesto Diaz-Flores et al.
CANCER RESEARCH (2019)
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia
Laurence C. Cheung et al.
HAEMATOLOGICA (2019)
NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2
Femke M. Hormann et al.
HAEMATOLOGICA (2019)
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia
David Marks et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group
Terzah M. Horton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition
Roger A. Habets et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331
Patrick A. Brown et al.
BLOOD (2019)
Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/Refractory ALL Patients
Xiaowen Tang et al.
BLOOD (2019)
How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia
Avraham Frisch et al.
HAEMATOLOGICA (2019)
BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
Sabina Chiaretti et al.
CANCER (2019)
Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Norman J. Lacayo et al.
BLOOD (2019)
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
Andrei V. Krivtsov et al.
CANCER CELL (2019)
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Zhaohui Gu et al.
NATURE GENETICS (2019)
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai et al.
BLOOD ADVANCES (2019)
Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia
M. Waibel et al.
LEUKEMIA (2018)
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Karen L. Bride et al.
BLOOD (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Eytan M. Stein et al.
BLOOD (2018)
Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
Avinash Bonda et al.
BONE MARROW TRANSPLANTATION (2018)
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
Elias Jabbour et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure
Yang Y. Ding et al.
HAEMATOLOGICA (2018)
Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ thorn Infant ALL
Michela Bardini et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure
Yang Y. Ding et al.
HAEMATOLOGICA (2018)
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Review
Stuart E. Siegel et al.
JAMA ONCOLOGY (2018)
Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia
Marlies Vanden Bempt et al.
CANCER CELL (2018)
Sequential CD19-and CD22-CART Cell Therapies for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Shuangyou Liu et al.
BLOOD (2018)
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia
Nicholas J. Short et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma
Yasmin Abaza et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2017)
Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP
Maoxiang Qian et al.
GENOME RESEARCH (2017)
Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia
Norbert Vey et al.
LEUKEMIA & LYMPHOMA (2017)
Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study
Jonathan Bond et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults
Kathryn G. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
Yu Liu et al.
NATURE GENETICS (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis
Donald A. Berry et al.
JAMA ONCOLOGY (2017)
Leukemia-initiating Cells in T-Cell Acute Lymphoblastic Leukemia
Shi Hao Tan et al.
FRONTIERS IN ONCOLOGY (2017)
Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report
Ge Zhang et al.
AMERICAN JOURNAL OF CASE REPORTS (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Diogo Gomes-Silva et al.
BLOOD (2017)
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group
Shalini C. Reshmi et al.
BLOOD (2017)
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Seong Lin Khaw et al.
BLOOD (2016)
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Sebastien Maury et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia
Zhaohui Gu et al.
NATURE COMMUNICATIONS (2016)
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
Yves Chalandon et al.
BLOOD (2015)
Monoclonal antibodies in acute lymphoblastic leukemia
Elias Jabbour et al.
BLOOD (2015)
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre-B-ALL
Aradhana Awasthi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
Dmitry Borkin et al.
CANCER CELL (2015)
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Matthew C. Stubbs et al.
CLINICAL CANCER RESEARCH (2015)
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Naval Daver et al.
HAEMATOLOGICA (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
Ute Fischer et al.
NATURE GENETICS (2015)
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2
Elizabeth A. Raetz et al.
PEDIATRIC BLOOD & CANCER (2015)
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Naval Daver et al.
HAEMATOLOGICA (2015)
90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study
Patrice Chevallier et al.
LANCET HAEMATOLOGY (2015)
Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia
Yuki Aoki et al.
BLOOD (2015)
Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study
Patrice Chevallier et al.
HAEMATOLOGICA (2015)
TKI Dasatinib Monotherapy for a Patient With Ph-Like ALL Bearing ATF7IP/PDGFRB Translocation
Kenichiro Kobayashi et al.
PEDIATRIC BLOOD & CANCER (2015)
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
Adele K. Fielding et al.
BLOOD (2014)
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia
Anjali S. Advani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
Triona Ni Chonghaile et al.
CANCER DISCOVERY (2014)
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Hagop Kantarjian et al.
CANCER (2013)
Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion
Etienne Lengline et al.
HAEMATOLOGICA (2013)
Toward a NOTCH1/FBXW7/RAS/PTEN-Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study
Amelie Trinquand et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB-Positive Acute Lymphoblastic Leukemia
Brent W. Weston et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Yoav H. Messinger et al.
BLOOD (2012)
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2012)
Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols
Josep-Maria Ribera et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation
Nicola Goekbuget et al.
BLOOD (2011)
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Robin Foa et al.
BLOOD (2011)
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
Sara Raponi et al.
LEUKEMIA & LYMPHOMA (2011)
Genetic variegation of clonal architecture and propagating cells in leukaemia
Kristina Anderson et al.
NATURE (2011)
Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance
Priscilla P. L. Chiu et al.
BLOOD (2010)
Modulation of Antigen Expression in B-Cell Precursor Acute Lymphoblastic Leukemia During Induction Therapy is Partly Transient: Evidence for a Drug-Induced Regulatory Phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group
Michael N. Dworzak et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2010)
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
Deborah A. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
Deborah A. Thomas et al.
BLOOD (2009)
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Elaine Coustan-Smith et al.
LANCET ONCOLOGY (2009)
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
Monique L. Den Boer et al.
LANCET ONCOLOGY (2009)
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy
Michael N. Dworzak et al.
BLOOD (2008)
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties
Christoph le Viseur et al.
CANCER CELL (2008)
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
Victoria Del Gaizo Moore et al.
BLOOD (2008)
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
Daniel J. DeAngelo et al.
BLOOD (2007)
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia:: results of the GRAAPH-2003 study
Adrienne de Labarthe et al.
BLOOD (2007)
Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia
Charlotte V. Cox et al.
BLOOD (2007)
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Barbara Wassmann et al.
BLOOD (2006)
Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
A. Delannoy et al.
LEUKEMIA (2006)
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
DA Thomas et al.
CANCER (2006)
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia:: A phase II study by the Japan Adult Leukemia Study Group
M Yanada et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Life in the balance: how BH3-only proteins induce apoptosis
SN Willis et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
KH Lee et al.
LEUKEMIA (2005)
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
C Imai et al.
BLOOD (2005)
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-Cell malignancies: A report from the children's oncology group
SL Berg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies
J Kurtzberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia
M Towatari et al.
BLOOD (2004)
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
DA Thomas et al.
BLOOD (2004)
Mechanisms for T-cell selective cytotoxicity of arabinosylguanine
CO Rodriguez et al.
BLOOD (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL)
B Wassmann et al.
LEUKEMIA (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
